Krystal Biotech (NASDAQ:KRYS) Rating Reiterated by Cowen

Cowen reiterated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report report published on Monday, May 6th, AnalystRatings.com reports.

Several other research analysts also recently commented on the stock. Chardan Capital reaffirmed a buy rating and issued a $57.50 price target on shares of Krystal Biotech in a research note on Friday, March 29th. HC Wainwright reaffirmed a buy rating and issued a $32.00 price target on shares of Krystal Biotech in a research note on Friday, March 29th. ValuEngine upgraded shares of Krystal Biotech from a hold rating to a buy rating in a report on Monday, February 4th. Finally, Zacks Investment Research upgraded shares of Krystal Biotech from a hold rating to a buy rating and set a $28.00 target price on the stock in a report on Tuesday, January 8th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $37.01.

KRYS stock traded up $0.43 during trading on Monday, hitting $32.00. The company had a trading volume of 68,449 shares, compared to its average volume of 76,931. The company has a market capitalization of $465.52 million, a PE ratio of -32.99 and a beta of 0.59. Krystal Biotech has a 52-week low of $10.00 and a 52-week high of $38.95. The company has a debt-to-equity ratio of 0.03, a current ratio of 33.28 and a quick ratio of 33.28.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. Sell-side analysts forecast that Krystal Biotech will post -1.42 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in KRYS. Great Point Partners LLC bought a new stake in shares of Krystal Biotech in the 4th quarter valued at about $10,226,000. FMR LLC boosted its holdings in shares of Krystal Biotech by 32.1% in the 4th quarter. FMR LLC now owns 1,235,400 shares of the company’s stock valued at $25,672,000 after buying an additional 300,000 shares in the last quarter. Frazier Management LLC boosted its holdings in shares of Krystal Biotech by 40.0% in the 4th quarter. Frazier Management LLC now owns 875,000 shares of the company’s stock valued at $18,183,000 after buying an additional 250,000 shares in the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Krystal Biotech in the 4th quarter valued at about $3,629,000. Finally, Artal Group S.A. boosted its holdings in shares of Krystal Biotech by 83.3% in the 4th quarter. Artal Group S.A. now owns 275,000 shares of the company’s stock valued at $5,715,000 after buying an additional 125,000 shares in the last quarter. Institutional investors and hedge funds own 46.05% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.

Featured Story: What type of investment options does a Roth IRA provide?

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.